Serov Nikita, Vinogradov Vladimir
International Institute "Solution Chemistry of Advanced Materials and Technologies", ITMO University, Saint-Petersburg 191002, Russian Federation.
International Institute "Solution Chemistry of Advanced Materials and Technologies", ITMO University, Saint-Petersburg 191002, Russian Federation.
Adv Drug Deliv Rev. 2022 May;184:114194. doi: 10.1016/j.addr.2022.114194. Epub 2022 Mar 10.
The technology of drug delivery systems (DDSs) has demonstrated an outstanding performance and effectiveness in production of pharmaceuticals, as it is proved by many FDA-approved nanomedicines that have an enhanced selectivity, manageable drug release kinetics and synergistic therapeutic actions. Nonetheless, to date, the rational design and high-throughput development of nanomaterial-based DDSs for specific purposes is far from a routine practice and is still in its infancy, mainly due to the limitations in scientists' capabilities to effectively acquire, analyze, manage, and comprehend complex and ever-growing sets of experimental data, which is vital to develop DDSs with a set of desired functionalities. At the same time, this task is feasible for the data-driven approaches, high throughput experimentation techniques, process automatization, artificial intelligence (AI) technology, and machine learning (ML) approaches, which is referred to as The Fourth Paradigm of scientific research. Therefore, an integration of these approaches with nanomedicine and nanotechnology can potentially accelerate the rational design and high-throughput development of highly efficient nanoformulated drugs and smart materials with pre-defined functionalities. In this Review, we survey the important results and milestones achieved to date in the application of data science, high throughput, as well as automatization approaches, combined with AI and ML to design and optimize DDSs and related nanomaterials. This manuscript mission is not only to reflect the state-of-art in data-driven nanomedicine, but also show how recent findings in the related fields can transform the nanomedicine's image. We discuss how all these results can be used to boost nanomedicine translation to the clinic, as well as highlight the future directions for the development, data-driven, high throughput experimentation-, and AI-assisted design, as well as the production of nanoformulated drugs and smart materials with pre-defined properties and behavior. This Review will be of high interest to the chemists involved in materials science, nanotechnology, and DDSs development for biomedical applications, although the general nature of the presented approaches enables knowledge translation to many other fields of science.
药物递送系统(DDSs)技术在药物生产中已展现出卓越的性能和效果,许多获得美国食品药品监督管理局(FDA)批准的纳米药物都证明了这一点,这些纳米药物具有更高的选择性、可控的药物释放动力学和协同治疗作用。然而,迄今为止,基于纳米材料的特定用途DDSs的合理设计和高通量开发远非常规做法,仍处于起步阶段,主要原因是科学家在有效获取、分析、管理和理解复杂且不断增长的实验数据集方面能力有限,而这些数据集对于开发具有一系列所需功能的DDSs至关重要。与此同时,对于数据驱动方法、高通量实验技术、过程自动化、人工智能(AI)技术和机器学习(ML)方法而言,这项任务是可行的,这被称为科学研究的第四范式。因此,将这些方法与纳米医学和纳米技术相结合,有可能加速具有预定义功能的高效纳米制剂药物和智能材料的合理设计和高通量开发。在本综述中,我们考察了迄今为止在应用数据科学、高通量以及自动化方法,并结合AI和ML来设计和优化DDSs及相关纳米材料方面所取得的重要成果和里程碑。本手稿的任务不仅是反映数据驱动纳米医学的最新进展,还展示相关领域的最新发现如何改变纳米医学的形象。我们讨论了所有这些结果如何用于推动纳米医学向临床转化,以及突出未来在开发、数据驱动、高通量实验和AI辅助设计方面的方向,以及生产具有预定义特性和行为的纳米制剂药物和智能材料。本综述将引起参与生物医学应用材料科学、纳米技术和DDSs开发的化学家的高度兴趣,尽管所介绍方法的通用性使知识能够转化到许多其他科学领域。